The Department of Health and Human Services today announced a $226 million contract to expand the nation’s capacity to quickly produce vaccine for a flu pandemic. HHS expects the six-year agreement with Sanofi Pasteur to increase the company’s capacity to use recombinant vaccine technology, which is faster than traditional egg-based technology, to produce a pandemic vaccine in the United States to nearly 100 million doses. Sanofi is the only company with a seasonal recombinant flu vaccine licensed in the U.S. “Keeping vaccine manufacturing in the United States is essential to protect Americans from pandemic influenza and to save lives,” said BARDA Director Rick Bright. “Better, faster vaccine technologies, produced in the U.S. will improve access, protect more people and, ultimately, strengthen our nation’s health security.” In September, President Trump created an interagency task force to develop and implement a five-year plan to improve flu vaccines and produce them faster.

 

Related News Articles

Headline
Adam Myers, M.D., population health chief at Cleveland Clinic, talks with Nancy Foster, AHA vice president for quality and patient safety, about preventing flu…
Headline
The Food and Drug Administration yesterday released an updated template for developers requesting emergency use authorization for antigen tests for…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s United Against the Flu campaign today released new…
Headline
In this AHA podcast, Rita Carreon, deputy vice president for health, UnidosUS, and Elisa Arespacochaga, vice president of the AHA’s Physician Alliance, discuss…
Headline
The American Medical Association today released for immediate use Current Procedural Terminology codes for reporting on medical claims two laboratory tests (…
Headline
A new Centers for Disease Control and Prevention study suggests that social distancing and other measures to stop the spread of SARS-CoV-2 could help reduce…